ClinicalTrials.gg
CompletedNCT02249065Updated Aug 1, 2022Results posted

Mirvaso in Use Study

A Phase 4 interventional study of Brimonidine in Rosacea, sponsored by Galderma R&D. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-01.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
205
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing brimonidine in Rosacea — none open to participants now, none under way, none of them phase 3. brimonidine · Rosacea.

Enrollment
6th of 11
205 · median 205
Started
2014
with 1 other
Phase 4
4 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
8 of 11
Galderma R&D

Among the 11 studies testing brimonidine in Rosacea, this one is the 6th largest by enrollment, is one of 2 that started in 2014, is one of 4 in phase 4, and was the 7th registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 22 are open to participants now.

Browse Rosacea studies →

Open to participants now

None of the 11 studies testing brimonidine in Rosacea is open now. The open studies under Rosacea, anywhere →

Where they have run

About brimonidine

brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing brimonidine in Rosacea as a file.
02

Study summary

This study is designed to:

  1. assess the signs and symptoms of rosacea, including erythema, without treatment and during treatment with Mirvaso® gel
  2. further characterize lifestyle impact and patient satisfaction with Mirvaso® treatment
  3. gain a better understanding of the real-world use of Mirvaso® on the pattern and management of facial erythema of rosacea.
03

Conditions studied

  • Rosacea

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must be 18 years of age or older at time of study consent.
  2. Subjects with a board certified dermatologist (BCD) clinical diagnosis of facial erythema of rosacea and eligible for treatment with Mirvaso® (brimonidine) topical gel, 0.33% per package insert.
  3. Subjects with a clinician's erythema assessment (CEA) score of \~3 at Screening Visit 1.
  4. Subjects with less than 3 facial inflammatory lesions of rosacea at Screening/Visit 1.
  5. Subjects must be willing and able to give written including photography consent. Consent and photo consent will be obtained prior to any study related procedures
  6. Females of with a negative urine pregnancy test (UPT) at Visit 1 (prior to test article application) or females of non-childbearing potential (deemed as [absence of menstrual bleeding for at least 1 year prior to enrollment], hysterectomy or bilateral oophorectomy).

Exclusion criteria

Exclusion Criteria:

  1. Subjects with particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin) or other concomitant facial dermatoses that are similar to rosacea such as peri-oral dermatitis, demodicidosis, facial keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, or actinic telangiectasia.
  2. Subjects with current diagnosis of Raynaud's syndrome, thromboangiitis obliterans, orthostatic hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal or hepatic impairment, scleroderma, Sjogren's syndrome or depression.
  3. Subjects with previous refractive eye surgery such as photorefractive keratectomy, laser-assisted sub-epithelial keratectomy, or laser-assisted in situ keratomileusis.
  4. Current treatment with monoamine oxidase inhibitors.
  5. Current treatment with barbiturates, opiates, sedatives, systemic anesthetics, or alpha- agonists.
  6. Less than 3 months (90 days) stable dose treatment with tricyclic antidepressants, cardiac glycosides, beta blockers or other antihypertensive agents.
  7. Subjects with any uncontrolled chronic or serious disease or medical condition that would normally prevent participation in a clinical study, or, in the judgment of the investigator, would put the subjects at undue risk, or might confound the study assessments (e.g., other dermatological diseases), or might interfere with the subjects' participation in the study, (e.g., planned hospitalization during the study).
  8. Subjects who have received, applied, or taken treatments with drugs, cosmetics or devices known to cause facial erythema and who are deemed ineligible by the investigator.
  9. Subjects with known allergies or sensitivities to any component of the study drug, including the active ingredient brimonidine tartrate label (refer to the package insert for Mirvaso® (brimonidine) topical gel, 0.33%).
  10. Subjects with prior treatment with brimonidine gel, oxymetazoline or other (topical and/or systemic) alpha adrenergic agonists.
  11. Subjects who are pregnant or breast-feeding or planning to become pregnant during the course of the study.
  12. Subjects exposed to excessive ultraviolet (UV) radiation within I week prior to baseline and/or subject was unwilling to refrain from excessive exposure to UV radiation during the course of the study.
  13. Subjects with the presence of a beard or excessive facial hair that would interfere with the study treatments or study assessments as deemed by the investigator, and refusal to remove beard or facial hair for duration of the study.
  14. Subjects with non-stable dose of current (last 60 days) use of prescription rosacea medications.
  15. Subjects with uncontrolled rosacea associated with inflammatory pustules and papules.
  16. Study site staff, relatives of staff members, or other individuals who would have access to the clinical study protocol.
  17. Subjects with participation in any study within 30 days of entry into this study or concomitantly with this study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
205 participants (actual)

Study arms

  • Experimental
    Mirvaso Gel

    Brimonidine topical gel, 0.33%

    Drug: Brimonidine

Interventions

06

What researchers measure

Primary outcomes

  1. Pre-Treatment Clinician Erythema Assessment (CEA)

    The number and percent of subjects in each CEA score category at each visit. CEA was conducted at the screening/baseline visit and all subsequent visits prior to the study drug application.

    Time frame: 14 days (Day 1 (Baseline), Day 7, and Day 14/Exit)

Secondary outcomes

  1. Subject Facial Redness Questionnaire

    Facial Redness Questionnaire at Day 1 and Day 14 (Mean Number of Subjects Who's Responses Indicate They Were/Were Not Bothered By Facial Redness, Across All 11 Facial Redness Questions)

    Time frame: 14 days (Day 1 (Baseline) and Day 14/Exit)

  2. Subject Treatment Satisfaction Questionnaire

    Mean Subject Treatment Satisfaction at Day 14 (Average Response Across 12 Questions)

    Time frame: 14 days (Day 14/Exit)

  3. Facial Redness Visual Analog Scale (VAS)

    The number and percent of subjects in each transformed response category for the in-office subject reported facial redness VAS

    Time frame: 14 days (Day 1 (Baseline), Day 14/Exit)

  4. Inflammatory Lesions

    Change from baseline in facial inflammatory lesion count

    Time frame: 14 days (Day 1 (Baseline) and Day 14/Exit)

07

Results

Posted Oct 19, 2017
Limitations and caveats
Open label, single arm, short duration.

Participant flow

Participant flow — Overall Study
MilestoneMirvaso Gel
Started205
Treated181
Completed176
Not completed29

Outcome measures

PrimaryPre-Treatment Clinician Erythema Assessment (CEA)

The number and percent of subjects in each CEA score category at each visit. CEA was conducted at the screening/baseline visit and all subsequent visits prior to the study drug application.

Time frame:
14 days (Day 1 (Baseline), Day 7, and Day 14/Exit)
Reported as:
Count of participants · Participants
Pre-Treatment Clinician Erythema Assessment (CEA)
ParticipantsMirvaso Gel
Day 1 (Baseline) — Clear Skin0
Day 1 (Baseline) — Almost Clear0
Day 1 (Baseline) — Mild Erythema7
Day 1 (Baseline) — Moderate Erythema144
Day 1 (Baseline) — Severe Erythema30
Day 1 (Baseline) — Missing0
Day 7 — Clear Skin3
Day 7 — Almost Clear18
Day 7 — Mild Erythema39
Day 7 — Moderate Erythema84
Day 7 — Severe Erythema24
Day 7 — Missing13
Day 14 — Clear Skin4
Day 14 — Almost Clear25
Day 14 — Mild Erythema39
Day 14 — Moderate Erythema86
Day 14 — Severe Erythema27
Day 14 — Missing0
SecondarySubject Facial Redness Questionnaire

Facial Redness Questionnaire at Day 1 and Day 14 (Mean Number of Subjects Who's Responses Indicate They Were/Were Not Bothered By Facial Redness, Across All 11 Facial Redness Questions)

Time frame:
14 days (Day 1 (Baseline) and Day 14/Exit)
Reported as:
Mean · Participants
Subject Facial Redness Questionnaire
ParticipantsMirvaso Gel
Not Bothered (Mean [SD], Day 1, Baseline)75.3 ± 39.4
Bothered (Mean [SD], Day 1, Baseline)104.7 ± 40.3
Missing (Day 1, Baseline)1 ± 0
Not Bothered (Mean [SD], Day 14)112.6 ± 28.9
Bothered (Mean [SD], Day 14)67.3 ± 26.2
Missing (Day 14)1.1 ± .3
SecondarySubject Treatment Satisfaction Questionnaire

Mean Subject Treatment Satisfaction at Day 14 (Average Response Across 12 Questions)

Time frame:
14 days (Day 14/Exit)
Reported as:
Mean · Participants
Subject Treatment Satisfaction Questionnaire
ParticipantsMirvaso Gel
Satisfied Participants (Mean [SD])127.3 ± 22.2
Dissatisfied Participants (Mean [SD])52.7 ± 22.2
Missing1.0 ± 0.0
SecondaryFacial Redness Visual Analog Scale (VAS)

The number and percent of subjects in each transformed response category for the in-office subject reported facial redness VAS

Time frame:
14 days (Day 1 (Baseline), Day 14/Exit)
Reported as:
Count of participants · Participants
Facial Redness Visual Analog Scale (VAS)
ParticipantsMirvaso Gel
Day 1 — None1
Day 1 — Very Mild31
Day 1 — Mild57
Day 1 — Moderate48
Day 1 — Severe38
Day 1 — Very Severe6
Day 14 — None1
Day 14 — Very Mild63
Day 14 — Mild45
Day 14 — Moderate44
Day 14 — Severe22
Day 14 — Very Severe6
SecondaryInflammatory Lesions

Change from baseline in facial inflammatory lesion count

Time frame:
14 days (Day 1 (Baseline) and Day 14/Exit)
Reported as:
Mean · lesions
Inflammatory Lesions
lesionsMirvaso Gel
Day 1: Lesions.6 ± 1.2
Day 14: Lesions1.5 ± 4.4
Day 14: Change From Baseline1 ± 3.9

Adverse events

Collected over 29 Days. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mirvaso Gel—3/181 (1.7%)68/181 (37.6%)
Most frequent serious events
Most frequent serious events
EventMirvaso Gel
myocardial infarctionCardiac disorders1/181
PericarditisCardiac disorders1/181
PneumoniaRespiratory, thoracic and mediastinal disorders1/181
Most frequent other events
Most frequent other events
EventMirvaso Gel
condition aggravatedGeneral disorders33/181
rosaceaSkin and subcutaneous tissue disorders21/181
ErythemaSkin and subcutaneous tissue disorders7/181
nasopharyngitisInfections and infestations6/181
feeling hotGeneral disorders4/181

Baseline characteristics

ITT Population, Subjects who received at least 1 application of study drug, and completed at least 1 assessment

Age, Categorical
Age, Categorical(Participants)Mirvaso Gel
<=18 years0
Between 18 and 65 years143
>=65 years38
Age, Continuous
Age, Continuous(years)Mirvaso Gel
Mean52.4 (22.0 to 85.0)
Sex: Female, Male
Sex: Female, Male(Participants)Mirvaso Gel
Female136
Male45
Region of Enrollment
Region of Enrollment(Participants)Mirvaso Gel
United States181
08

Study locations

12 sites
  • Johnson Dermatology
    Fort Smith, Arkansas 72916, United States
  • Blue Harbor Dermatology
    Newport Beach, California 92663, United States
  • Center for Dermatology and Laser Surgery
    Sacramento, California 95819, United States
  • Redwood Dermatology Research
    Santa Rosa, California 95403, United States
  • Florida Academic Dermatology Center
    Miami, Florida 33136, United States
  • Research Institute of the Southeast
    West Palm Beach, Florida 33401, United States
  • Grekin Skin Institute
    Warren, Michigan 48088, United States
  • Advanced Skin Research Center
    Omaha, Nebraska 68144, United States
  • Manhattan Dermatology and Cosmetic Surgery
    New York, New York 10017, United States
  • DermDox Centers for Dermatology
    Hazleton, Pennsylvania 18201, United States
  • Arlington Research Center
    Arlington, Texas 76011, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2017, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2014
First posted
Sep 25, 2014
Start
Sep 2014
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Results first posted
Oct 19, 2017
Last update
Aug 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02249065
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Sep 25, 2014
Start date
Sep 2014
Primary completion
Aug 2015
Completion
Aug 2015
Results posted
Oct 19, 2017
Last update
Aug 1, 2022

Study contacts

Jeffrey Sugarman, MD
principal investigator · Redwood Dermatology Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion